// App-Quantinova.ai

1192 : Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E

Researchers

Presenter

  • Sanjal H Desai

Principal Investigators

  • Betsy Laplant

  • William R. Macon

  • Rebecca L. King

  • Yucai Wang

  • David J. Inwards

  • Ivana Micallef

  • Patrick B. Johnston

  • Luis F. Porrata

  • Stephen M. Ansell

  • Thomas M. Habermann

  • Thomas E. Witzig

  • Grzegorz S. Nowakowski

Medical Centers

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

  • Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

  • Mayo Clinic, Rochester, MN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Follicular lymphoma

  • B cell lymphomas

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Pegfilgrastim

  • Lenalidomide

  • Vincristine

  • Doxorubicin

  • Prednisone

  • Rituximab

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT00670358

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved